재조합 인플루엔자 백신과 불활성화 인플루엔자 백신의 면역원성 비교

• 영문명: Immunogenicity of Recombinant Influenza Vaccine Compared with Inactivated Influenza Vaccine on the Prevention of Influenza Virus: A Systematic Review and Meta-analysis
• 발행기관: 대한약학회
• 저자명: 차윤선(Youn-Sun Cha) 안은지(Eun-Ji An) 권순홍(Sun-Hong Kwon) 이의경(Eui-Kyung Lee)
• 간행물 정보: 『약학회지』제68권 제1호(2024년), 71~78쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.02.28

영문 초록

To compare surrogate markers of immunogenicity between recombinant and inactivated influenza vaccines, this study conducted a systematic review and meta-analysis for each strain. Three databases of Medline (Pubmed), Embase and Cochrane Central were searched to identify all published literature up to July 2023. Out of a total of 1,658 initially identified articles, 14 randomized controlled trials were selected based on inclusion and exclusion criteria. The program R version 4.3.1 was used to estimate the mean difference of geometric mean titer (GMT) and the pooled risk ratio (RR) of seroconversion and seroprotection with 95% confidence intervals. The meta-analysis results found higher GMT effect sizes for recombinant influenza vaccines compared to inactivated vaccines for A/H3N2 (MD=124.87, 95% CI 52.63-197.11) and B/Yamagata (MD=19.89, 95% CI 7.61-32.17) strains. In terms of seroconversion rates, recombinant influenza vaccines exhibited higher seroconversion for A/H3N2 (RR=1.33, 95% CI 1.26-1.40) and B/Yamagata (RR=1.75, 95% CI 1.06-2.89) strains. Slightly higher seroprotection rates were observed for A/H3N2 (RR=1.04, 95% CI 1.02-1.07) and B/Yamagata (RR=1.07, 95% CI 1.01-1.13) strains with recombinant vaccines. The findings from this study contribute valuable evidence for regulatory decisions when introducing recombinant vaccines in South Korea.

목차

서론(Introduction)

방법(Methods)

결과(Results)

고찰(Discussion)

결론(Conclusion)

Conflict of Interest

References

키워드

Influenza vaccine Immunogenicity Systematic review Meta-analysis